get a key
steadybase-$ company VOR
account_id none on file
legal_name Vor Biopharma Inc.
ticker VOR
cik 1817229
domain vorbio.com
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
calls 0 filings 11 executives 2 family 0
why_nownone on file
callsnone on file
filings
• costs of consultants, including their fees and related travel expenses; • costs related to compliance with quality and regulatory requirements; • costs of laboratory supplies and acquiring and developing preclinical and clinical trial materials, including expenses associated with our clinical manufacturing organizations (“CMOs”); and • payments made and consideration issued under third party licensing agreeme

filing / Aug 11, 2026 / receipt

-related services and other consulting fees, facility-related expenses, which include depreciation costs and other allocated expenses for rent and maintenance of facilities, insurance costs, recruiting costs, travel expenses and other general administrative expenses.

filing / Aug 11, 2026 / receipt

There was also a decrease of $7.1 million in salaries and benefits expenses primarily due to severance costs incurred in connection with employee terminations in the prior year period.

filing / Aug 11, 2026 / receipt

There was also a decrease of $12.7 million in salaries and benefits expenses primarily due to severance costs incurred in connection with employee terminations in the prior year period, and also due in part to a decreased headcount compared to the prior year period.

filing / Aug 11, 2026 / receipt

Contractual obligations relate to future minimum lease payments for an existing non-cancellable lease relating to corporate office space, with a term expiring in August 2031.

filing / Aug 11, 2026 / receipt

In August 2025, the Company entered into a lease agreement for office space (“Boylston Lease”) with 500 Boylston & 222 Berkeley Owner (DE) LLC (the “Boylston Landlord”).

filing / Aug 11, 2026 / receipt

• costs of consultants, including their fees and related travel expenses; • costs related to compliance with quality and regulatory requirements; • costs of laboratory supplies and acquiring and developing preclinical and clinical trial materials, including expenses associated with our clinical manufacturing organizations (“CMOs”); and • payments made and consideration issued under third party licensing agreeme

filing / May 13, 2026 / receipt

-related services and other consulting fees, facility-related expenses, which include depreciation costs and other allocated expenses for rent and maintenance of facilities, insurance costs, recruiting costs, travel expenses and other general administrative expenses.

filing / May 13, 2026 / receipt

Contractual obligations relate to future minimum lease payments for an existing non-cancellable lease relating to corporate office space, with a term expiring in August 2031.

filing / May 13, 2026 / receipt

In August 2025, the Company entered into a lease agreement for office space (“Boylston Lease”) with 500 Boylston & 222 Berkeley Owner (DE) LLC (the “Boylston Landlord”).

filing / May 13, 2026 / receipt

Digital Technology Lead - Data and AI

company_statement / Jul 1, 2026 / receipt

executives
Qing Zuraw Chief Development Officer - receipt
Sandesh Mahatme Chief Financial Officer - receipt
familynone on file
upcoming
2026-11-12 earnings call scheduled ir
changes
2025-07-22 Chief Development Officer, appointed sec_8k
2025-07-10 Chief Financial Officer, appointed sec_8k
mcp_package_hint
steadybase-$